It was acknowledged that a certain volume for biosimilars will be required to reduce costs in the future, especially with the prospect of other insulins soon facing biosimilar competition (e.g. insulin aspart) and the increasing financial burden of diabetes treatment. Here, INS is linked to diabetes mellitus.